| mitoglitazone (MSDC-0160) / Metabolic Solutions |
NCT01103414: Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients |
|
|
| Completed | 2b | 356 | US | Mitoglitazone, MSDC-0160, Pioglitazone, ACTOS, Placebo | Metabolic Solutions Development Company | Type 2 Diabetes | 11/11 | 12/11 | | |
NCT00760578: A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator |
|
|
| Completed | 2a | 86 | US | Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg | Metabolic Solutions Development Company | Type 2 Diabetes Mellitus | 01/09 | 02/09 | | |
NCT01374438: 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease |
|
|
| Completed | 2 | 29 | US | MSDC-0160, Mitoglitazone, Placebo | Metabolic Solutions Development Company | Alzheimer's Disease | 03/13 | 05/13 | | |
